The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Bladder Cancer MORE >>

By testing circulating tumor DNA at critical time points throughout neoadjuvant chemotherapy and cystectomy, clinicians may be able to better predict which patients with advanced bladder cancer would likely benefit from additional systemic therapies, according to results of a study published in the Journal of Clinical Oncology.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.